Drug intelligence / Profile preview

YR-002

Development stage: Preclinical
Lead developer: Hangzhou Yirui Pharmaceutical Technology
Modality: Small Molecules

Overview

YR-002 is a small molecule ion channel inhibitor currently in preclinical development by Hangzhou Yirui Pharmaceutical Technology (also known as Yirui Pharmaceutical Technology). The drug is specifically designed to target ion channels involved in the transmission of sensory signals related to itching. It is being investigated for the treatment of pruritus (itching) associated with various skin and musculoskeletal diseases. As a targeted small molecule, YR-002 aims to provide a more specific therapeutic approach to managing chronic itch compared to traditional systemic treatments.

Beyond the preview

Go deeper on YR-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YR-002.

Explore the full profile